ORITINIV DIN 02561042
Status: Approved
Holder: XEDITON PHARMACEUTICALS INC
Health Canada record
| Active ingredient(s) | ORITAVANCIN (ORITAVANCIN PHOSPHATE) 400 MG |
|---|
| Dosage form | Powder For Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | J01XA05 ORITAVANCIN |
|---|
| Original market date | |
|---|
| Current status date | 12-Sep-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Xediton Pharmaceuticals Inc — licence 101770, currently licensed, last inspection rating C (2026-06-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ORITAVANCIN (ORITAVANCIN PHOSPHATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02561050 | ORITINIV | XEDITON PHARMACEUTICALS INC | Powder For Solution | ORITAVANCIN (ORITAVANCIN PHOSPHATE) 1200 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36018 | 2025-09-12 | New Drug Submission (NDS) | |
Request a quote for ORITINIV
How to read a Canadian DIN record